November 2, 2021
Life Sciences
  • Eli Lilly and Co. announced that the U.S. government bought 614,000 additional doses of its COVID-19 antibody therapy for $1.29 billion. As part of the agreement, Lilly will supply a minimum of 400,000 doses of bamlanivimab with etesevimab no later than December 31, 2021, and the remaining doses by January 31, 2022. (Press release here)